

Edgar Filing: NEOPROBE CORP - Form 424B3

NEOPROBE CORP
Form 424B3
May 15, 2002

Filed Pursuant to Rule 424(b) (3)
Registration No. 333-84782

PROSPECTUS SUPPLEMENT

to

Prospectus dated May 3, 2002

of

NEOPROBE CORPORATION

5,898,876 SHARES OF COMMON STOCK

The date of this prospectus supplement is May 15, 2002.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-QSB

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE QUARTERLY PERIOD ENDED: MARCH 31, 2002

OR

TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT

FOR THE TRANSITION PERIOD FROM _____ TO _____

COMMISSION FILE NUMBER: 0-26520

NEOPROBE CORPORATION
(Exact name of small business issuer as specified in its charter)

DELAWARE
(State or other jurisdiction of
incorporation or organization)

31-1080091
(I.R.S. employer identification no.)

425 METRO PLACE NORTH, SUITE 300, DUBLIN, OHIO 43017
(Address of principal executive offices)

614.793.7500
(Issuer's telephone number)

36,450,067 SHARES OF COMMON STOCK, PAR VALUE \$.001 PER SHARE

Edgar Filing: NEOPROBE CORP - Form 424B3

(Number of shares of issuer's common equity outstanding
as of the close of business on April 26, 2002)

Transitional Small Business Disclosure Format (check one) Yes | | No |X|

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

NEOPROBE CORPORATION AND SUBSIDIARY CONSOLIDATED BALANCE SHEETS

ASSETS	MARCH 31, 2002 (UNAUDITED)	DECEMBER 31, 2001
	-----	-----
Current assets:		
Cash and cash equivalents	\$1,206,739	\$ 4,287,101
Available-for-sale securities	2,473,870	--
Accounts receivable, net	186,006	561,129
Inventory	1,323,490	1,430,908
Prepaid expenses and other	166,787	268,445
	-----	-----
Total current assets	5,356,892	6,547,583
	-----	-----
Property and equipment	2,212,178	2,171,788
Less accumulated depreciation and amortization	1,606,895	1,502,676
	-----	-----
	605,283	669,112
	-----	-----
Patents and trademarks	3,187,510	3,183,639
Non-compete agreements	603,880	603,880
Acquired technology	245,131	245,131
	-----	-----
	4,036,521	4,032,650
Less accumulated amortization	267,386	122,697
	-----	-----
	3,769,135	3,909,953
	-----	-----
Other assets	211,041	202,258
	-----	-----
Total assets	\$9,942,351	\$11,328,906
	=====	=====

CONTINUED

Edgar Filing: NEOPROBE CORP - Form 424B3

LIABILITIES AND STOCKHOLDERS' EQUITY	MARCH 31, 2002 (UNAUDITED)

Current liabilities:	
Notes payable to finance company	\$ 95,325
Capital lease obligations, current	13,335
Accrued liabilities	907,661
Accounts payable	286,209
Deferred license revenue, current	800,000

Total current liabilities	2,102,530

Capital lease obligations	16,515
Deferred license revenue	1,200,000
Contingent consideration for acquisition	429,776
Other liabilities	130,644

Total liabilities	3,879,465

Commitments and contingencies	--
Stockholders' equity:	
Preferred stock; \$.001 par value; 5,000,000 shares authorized at March 31, 2002 and December 31, 2001; none issued and outstanding (500,000 shares designated as Series A, \$.001 par value, at March 31, 2002 and and December 31, 2001; none outstanding)	--
Common stock; \$.001 par value; 50,000,000 shares authorized; 36,449,067 shares issued and outstanding at March 31, 2002; and at December 31, 2001	36,449
Additional paid-in capital	124,592,341
Accumulated deficit	(118,559,536)
Unrealized loss on available-for-sale securities	(6,368)

Total stockholders' equity	6,062,886

Total liabilities and stockholders' equity	\$ 9,942,351
	=====

See accompanying notes to the financial statements

Edgar Filing: NEOPROBE CORP - Form 424B3

	THREE MONTHS ENDED MARCH 31,	
	2002	2001
Revenues:		
Net sales	\$ 735,304	\$ 1,395,669
License revenue and other	325,000	350,000
Total revenues	1,060,304	1,745,669
Cost of goods sold	493,510	948,830
Gross profit	566,794	796,839
Operating expenses:		
Research and development	539,756	199,791
Selling, general and administrative	874,807	570,109
Total operating expenses	1,414,563	769,900
(Loss) income from operations	(847,769)	26,939
Other income (expense):		
Interest income	16,952	50,155
Interest expense	(2,835)	(3,134)
Other	(11,473)	7,128
Total other income	2,644	54,149
Net (loss) income	\$ (845,125)	\$ 81,088
(Loss) income per common share:		
Basic	\$ (0.02)	\$ --
Diluted	\$ (0.02)	\$ --
Weighted average shares outstanding:		
Basic	36,009,067	25,894,955
Diluted	36,009,067	26,086,569

See accompanying notes to the financial statements

Edgar Filing: NEOPROBE CORP - Form 424B3

	MARCH 31,	
	2002	2001
Cash flows from operating activities:		
Net (loss) income	\$ (845,125)	\$ 81,088
Adjustments to reconcile net (loss) income to net cash used in operating activities:		
Depreciation and amortization	248,912	103,131
Change in operating assets and liabilities:		
Accounts receivable	393,089	(123,556)
Inventory	100,229	(409,228)
Accounts payable	(207,356)	(381,975)
Deferred license revenue	(200,000)	(200,000)
Other assets and liabilities	50,316	114,103
	-----	-----
Net cash used in operating activities	(459,935)	(816,437)
	-----	-----
Cash flows from investing activities:		
Purchases of available-for-sale securities	(2,491,361)	--
Purchases of property and equipment	(29,328)	(12,551)
Proceeds from sales of property and equipment	--	925
Patent and trademark costs	(3,871)	(8,842)
Subsidiary acquisition costs	(23,826)	--
	-----	-----
Net cash used in investing activities	(2,548,386)	(20,468)
	-----	-----
Cash flows from financing activities:		
Proceeds from issuance of common stock, net	--	834
Payment of offering costs	(2,426)	--
Payment of notes payable	(66,540)	(44,568)
Payments under capital leases	(3,075)	(2,704)
	-----	-----
Net cash used in financing activities	(72,041)	(46,438)
	-----	-----
Net decrease in cash and cash equivalents	(3,080,362)	(883,343)
Cash and cash equivalents, beginning of period	4,287,101	4,643,347
	-----	-----
Cash and cash equivalents, end of period	\$ 1,206,739	\$ 3,760,004
	=====	=====

See accompanying notes to the financial statements

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PRESENTATION

Edgar Filing: NEOPROBE CORP - Form 424B3

The information presented for March 31, 2002 and 2001, and for the periods then ended is unaudited, but includes all adjustments (which consist only of normal recurring adjustments) that the management of Neoprobe Corporation (Neoprobe, we or the Company) believes to be necessary for the fair presentation of results for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The results for the interim period are not necessarily indicative of results to be expected for the year. The financial statements should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2001, which were included as part of the Company's Annual Report on Form 10-KSB. Certain 2001 amounts have been reclassified to conform with the 2002 presentation (see Note 10).

The consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Cardiosonix Ltd. (Cardiosonix) beginning December 31, 2001 (see Note 10). All significant inter-company accounts were eliminated in consolidation.

2. COMPREHENSIVE INCOME (LOSS)

Due to the Company's net operating loss position, there are no income tax effects on comprehensive income (loss) components for the three months ended March 31, 2002.

	THREE MONTHS ENDED MARCH 31, 2002
Net loss	\$845,125
Unrealized losses on securities	6,368

Other comprehensive loss	\$851,493
	=====

The Company had no accumulated other comprehensive income (loss) activity during the three-month period ended March 31, 2001.

3. EARNINGS PER SHARE

Basic earnings per share is calculated using the weighted average number of common shares outstanding during the periods. Diluted earnings per share is calculated using the weighted average number of common shares outstanding during the periods, adjusted for the effects of convertible securities, options and warrants, if dilutive.

THREE MONTHS ENDED MARCH 31, 2002		THREE MO MARCH
BASIC EARNINGS PER SHARE	DILUTED EARNINGS PER SHARE	BASIC EARNINGS PER SHARE

Edgar Filing: NEOPROBE CORP - Form 424B3

Outstanding shares	36,449,067	36,449,067	26,265,770
Effect of weighting changes in outstanding shares	--	--	(815)
Contingently issuable shares	(440,000)	(440,000)	(370,000)
Stock options	--	--	--
Adjusted shares	36,009,067	36,009,067	25,894,955

6

The following table summarizes options to purchase common stock of the Company which were outstanding during the three-month period ended March 31, 2001, but which were not included in the computation of diluted income per share because their effect was anti-dilutive.

THREE MONTHS ENDED MARCH 31, 2001	
EXERCISE PRICE	OPTIONS OUTSTANDING
\$ 0.41 - \$ 1.25	405,972
\$ 1.50 - \$ 2.50	227,520
\$ 3.25 - \$ 6.00	269,700
\$13.38 - \$15.75	92,500
	995,692
	=====

There is no difference in basic and diluted earnings per share for the Company related to the three months ended March 31, 2002. The net loss per common share for this period excludes the number of common shares issuable upon exercise of outstanding stock options and warrants into the Company's common stock since such inclusion would be anti-dilutive.

4. INVENTORY

The components of inventory are as follows:

	MARCH 31, 2002	DECEMBER 31, 2001
Materials and component parts	\$ 804,811	\$ 807,393
Work in process	147,572	--
Finished goods	371,107	623,515
	=====	=====
	\$1,323,490	\$1,430,908

Edgar Filing: NEOPROBE CORP - Form 424B3

5. LINE OF CREDIT

During February 2002, the Company entered into a line of credit facility with an investment management company. The facility provides for a maximum line of credit of \$2.0 million and is fully collateralized by pledged cash and investments on deposit with the investment management company. Availability under the facility is based on advance rates varying from 80% to 92% of the underlying available collateral. Outstanding amounts under the facility bear interest at LIBOR plus 175 basis points. The facility expires in February 2007. There was no outstanding balance under the line of credit as of March 31, 2002.

6. INCOME TAXES

For the quarter ended March 31, 2001, the reversal of certain temporary differences related to accrued expenses and deferred revenue resulted in the generation of a loss for income tax purposes. As a result, no income tax expense is reflected in the statement of operations for the quarter ended March 31, 2001. All of the Company's net deferred tax assets have been fully offset by a valuation allowance.

7

7. STOCK OPTIONS

During the first quarter of 2002, the Board of Directors granted options to employees and certain directors of the Company to purchase 890,000 shares of common stock, exercisable at an average price of \$0.42 per share, vesting over three years. As of March 31, 2002, the Company has 2.8 million options outstanding under two stock option plans. Of the outstanding options, 1.0 million options have vested as of March 31, 2002, at an average exercise price of \$0.88 per share.

8. AGREEMENTS

During January 2002, the Company completed a license agreement with the University of California, San Diego (UCSD) for a proprietary compound that the Company believes could be used as a lymph node locating agent in intraoperative lymphatic mapping (ILM) procedures. The license agreement is effective until the later of the expiration date of the longest-lived underlying patent or January 30, 2023. Under the terms of the license agreement, UCSD has granted the Company the exclusive rights to make, use, sell, offer for sale and import Licensed Products as defined in the agreement and to practice the defined Licensed Methods during the term of the agreement. The Company may also sublicense the Patent Rights, subject to the approval of certain sublicense terms by UCSD. In consideration for the license rights, the Company agreed to pay UCSD a license issue fee of \$25,000 and license maintenance fees of \$25,000 per year. The Company also agreed to pay UCSD milestone payments related to successful regulatory clearance for marketing of the Licensed Products, a royalty on Net Sales of Licensed Products subject to a \$25,000 minimum annual royalty, fifty percent of all sublicense fees and fifty percent of sublicense royalties. The Company also agreed to reimburse UCSD for all patent-related costs.

UCSD also has the right to terminate the agreement or change the nature of the agreement to a non-exclusive agreement if the Company is determined not to have been diligent in developing and commercializing the covered products, not marketing the products within six months of receiving regulatory approval, reasonably filling market demand or obtaining all the

Edgar Filing: NEOPROBE CORP - Form 424B3

necessary government approvals.

9. SEGMENT AND SUBSIDIARY INFORMATION

The Company owns or has rights to intellectual property involving two primary types of medical diagnostic products, including gamma detection instruments currently used primarily in the application of ILM, and blood flow measurement devices.

8

The information in the following table is derived directly from the segment's internal financial reporting used for corporate management purposes. Selling, general and administrative costs, including amortization, interest and other costs that relate primarily to corporate activity, are not currently allocated to the operating segments.

(\$ AMOUNTS IN THOUSANDS)	GAMMA	BLOOD	UNALLOCA
THREE MONTHS ENDED MARCH 31, 2002	DETECTION	FLOW	-----
	-----	----	-----
Net sales:			
United States(1)	\$ 676	\$ --	\$ --
International	59	--	--
License revenue and other	325	--	--
Research and development expenses	283	256	--
Selling, general and administrative expenses	--	--	875
Income (loss) from operations(2)	284	(256)	(875)
Other income	--	--	3
 THREE MONTHS ENDED MARCH 31, 2001			
Net sales:			
United States(1)	\$1,328	\$ --	\$ --
International	68	--	--
License revenue and other	350	--	--
Research and development expenses	200	--	--
Selling, general and administrative expenses	--	--	570
Income (loss) from operations(2)	597	--	(570)
Other income	--	--	54

(1) All sales to Ethicon are made in the United States. Ethicon distributes the product globally through its international affiliates.

(2) Income (loss) from operations does not reflect the allocation of selling, general and administrative costs to the operating segments.

10. NEW ACCOUNTING PRONOUNCEMENTS

In July 2001, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 141, Business Combinations, and SFAS No. 142, Goodwill and Other Intangible Assets. Under SFAS 141, any business combination initiated after June 30, 2001 must be accounted for as a purchase. For purchase business combinations that are consummated after June 30, 2001, goodwill and identifiable intangibles should be recorded and amortized in accordance with SFAS 142, i.e., goodwill and intangible assets with indefinite lives are not

Edgar Filing: NEOPROBE CORP - Form 424B3

amortized and other identified intangibles are amortized. For any purchase business combination consummated on or before June 30, 2001, the accounting under APB 16 and APB 17 still applies. Goodwill and separately identifiable intangibles should be recorded and amortized until adopting SFAS 142, which is required for fiscal years beginning after December 15, 2001. A calendar year-end company would continue to amortize goodwill and all separately identifiable intangibles through December 31, 2001. Upon adoption of SFAS 142, a company would cease amortizing goodwill and separately identifiable intangibles with indefinite lives and amortize other identifiable intangibles in accordance with the guidelines set forth in the standard. The Company adopted SFAS 141 and SFAS 142 as of December 31, 2001 related to its acquisition of Cardiosonix. The adoption of these pronouncements resulted in recording \$3.5 million of acquired intangible assets with a weighted average useful life of approximately 13 years. During the first quarter of 2002, the Company recorded \$90,000 in amortization expense that is included in selling, general and administrative expenses, and recorded a purchase price adjustment of \$24,000 to the contingent consideration liability related to net acquisition costs in excess of initial estimates.

In October 2001, the FASB issued SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, which supersedes both SFAS 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of and the accounting and reporting provisions of APB Opinion No. 30, Reporting the Results of Operations--Reporting the Effects

9

of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions, for the disposal of a segment of a business (as previously defined in that Opinion). SFAS 144 retains the fundamental provisions in SFAS 121 for recognizing and measuring impairment losses on long-lived assets held for use and long-lived assets to be disposed of by sale, while also resolving significant implementation issues associated with SFAS 121. For example, SFAS 144 provides guidance on how a long-lived asset that is used as part of a group should be evaluated for impairment, establishes criteria for when a long-lived asset is held for sale, and prescribes the accounting for a long-lived asset that will be disposed of other than by sale. SFAS 144 retains the basic provisions of APB 30 on how to present discontinued operations in the income statement but broadens that presentation to include a component of an entity (rather than a segment of a business). Unlike SFAS 121, an impairment assessment under SFAS 144 will never result in a write-down of goodwill. Rather, goodwill is evaluated for impairment under SFAS 142, Goodwill and Other Intangible Assets.

The Company adopted the provisions of SFAS 144 for the quarter ended March 31, 2002. Management does not expect the adoption of SFAS 144 for long-lived assets held for use to have a material impact on the Company's financial statements because the impairment assessment under SFAS 144 is largely unchanged from SFAS 121. The provisions of the Statement for assets held for sale or other disposal generally are required to be applied prospectively after the adoption date to newly initiated disposal activities. The adoption of SFAS 144 did not have a material effect on the Company's financial statements for the first quarter of 2002.

In November 2001, the Emerging Issues Task Force of the FASB issued Topic D-103, Income Statement Characterization of Reimbursements Received for Out-of-Pocket Expenses Incurred. The FASB is requiring Topic D-103 be applied in financial reporting periods beginning after December 15, 2001.

Edgar Filing: NEOPROBE CORP - Form 424B3

Topic D-103 requires companies to characterize reimbursements received for out-of-pocket expenses as revenue. The adoption of Topic D-103 requirements resulted in the reclassification of the \$125,000 reimbursement by Ethicon of certain research and development charges from research and development expenses to license revenue and other for all periods presented.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS

Revenue for the first quarter of 2002 decreased \$685,000 to \$1.1 million from \$1.7 million for the same period in 2001. Research and development expenses during the first quarter of 2002 were \$540,000 or 38% of operating expenses for the quarter. Selling, general and administrative expenses were \$875,000 or 62% of operating expenses for the quarter. Overall, operating expenses for the first quarter of 2002 increased \$645,000 or 84% over the same quarter in 2001. The Company anticipates that total operating expenses for the remaining quarters of 2002 will be consistent with first quarter 2002 levels, except for research and development expenses that are expected to increase as a result of efforts to bring the first of the blood flow measurement devices to market.

Three months ended March 31, 2002 and 2001

Net Sales and Margins. Net product sales decreased \$660,000 or 47% to \$735,000 during the first quarter of 2002 from \$1.4 million during the same period in 2001. Gross margins on product sales remained constant at 33% of net sales for the first quarter of 2002 compared to 32% of net sales for the same period in 2001. The decline in net product sales was the result of lower unit sales in the first quarter of 2002 as compared to the first quarter of 2001. The Company did not ship all of the units originally committed to be purchased by our primary marketing partner, Ethicon Endo-Surgery, Inc. (Ethicon) due to delays in the transfer of manufacturing of the Company's neo2000(R) system to a new contract manufacturer. The transfer delays, coupled with declines in demand primarily associated with the Company's BlueTip(TM) probes from Ethicon and Ethicon's overstock position, decreased revenue for the quarter below prior years and current year expectations. Neoprobe initiated the manufacturing transfer in the fourth quarter of 2001 in order to achieve cost reduction and quality improvements. As a result of the technical delays in the transfer process, Neoprobe agreed with Ethicon to spread the delivery of committed units not shipped during the first quarter over the rest of the year.

10

License Revenue and Other. License revenue and other in the first quarters of 2002 and 2001 included \$200,000 from the pro-rata recognition of license fees related to the distribution agreement with Ethicon and \$125,000 from the reimbursement by Ethicon of certain product development costs.

Research and Development Expenses. Research and development expenses increased \$340,000 or 170% to \$540,000 during the first quarter of 2002 from \$200,000 during the same period in 2001. The increase is primarily due to the product development efforts of Cardiosonix, additional Neoprobe headcount to support Cardiosonix activities, and \$55,000 in gamma detection drug development costs.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased \$305,000 or 53% to \$875,000 during the first quarter of 2002 from \$570,000 during the same period in 2001. The increase was primarily a result of the general and administrative costs incurred in the operation of Cardiosonix, increased professional services incurred by the

Edgar Filing: NEOPROBE CORP - Form 424B3

Company related to Cardiosonix, the transfer of manufacturing of certain components of the neo2000 gamma detection system to a new contract manufacturer, and \$45,000 in impairment of intellectual property that the Company did not believe had ongoing value to the business.

Other Income. Other income decreased \$52,000 or 95% to \$3,000 during the first quarter of 2002 from \$54,000 during the same period in 2001. Other income during the first quarters of 2002 and 2001 consisted primarily of interest income. The Company's interest income decreased because the Company received a lower interest rate on its cash and investments during the first quarter of 2002 as compared to the same period in 2001, consistent with marketplace activity over the two periods.

LIQUIDITY AND CAPITAL RESOURCES

Operating Activities. Cash used in operations decreased \$357,000 to \$460,000 during the first quarter of 2002 from \$816,000 during the same period in 2001. Working capital decreased \$817,000 to \$3.3 million at March 31, 2002 as compared to \$4.1 million at December 31, 2001. The current ratio decreased slightly to 2.5 at March 31, 2002 from 2.6 at December 31, 2001. The decrease in working capital was primarily related to cash used to fund development activities, coupled with lower levels of accounts receivable and other working capital components at March 31, 2002 as compared to December 2001.

Cash and investment balances decreased to \$3.7 million at March 31, 2002 from \$4.3 million at December 31, 2001, primarily due to the requirements of supporting the operations of Cardiosonix and the decrease in net sales during the first quarter of 2002.

Accounts receivable decreased to \$186,000 at March 31, 2002 from \$561,000 at December 31, 2001. The Company expects receivable levels to fluctuate in 2002 depending on the timing of purchases and payments by Ethicon.

Inventory levels decreased to \$1.3 million at March 31, 2002 as compared to \$1.4 million at December 31, 2001 as control unit safety stock was used up due to the manufacturing transfer. During 2002, we will continue to work through our carryover stock of certain long-lead gamma device components that were built up during 2001 in order to take advantage of significant quantity price breaks. We expect inventory levels to remain relatively steady in the second and third quarters as the use of these long-lead components is offset by the re-establishment of our control unit safety stock. Later in 2002, we will also start to build inventory of blood flow products in preparation for commercial launch.

The Company continues to anticipate it will need to fund up to \$3.5 million in development and market support costs during 2002 related to preparing for the commercial launch of its blood flow product line, while the gamma detection product line is still expected to be break-even.

Investing Activities. Cash used in investing activities increased to \$2.5 million during the first quarter of 2002 from \$20,000 during the same period in 2001. During February and March 2002, the Company invested in \$2.5 million of available for sale securities. Capital expenditures in the first quarters of 2002

and 2001 were split between purchases of production tools and equipment and technology infrastructure. Capital needs for 2002 are expected to increase over 2001 to support instrument development and manufacturing activities, although it is our intent to initially outsource manufacturing of blood flow products as is

Edgar Filing: NEOPROBE CORP - Form 424B3

currently done for our gamma devices.

Financing Activities. Financing activities used \$72,000 in cash in the first quarter of 2002 versus \$46,000 during the same period in 2001. Payments of notes payable were 50% higher during the first quarter of 2002 as compared to the same period in 2001, due to the increased cost of financed insurance.

On November 19, 2001, the Company entered into a common stock purchase agreement with an investment fund, Fusion Capital Fund II, LLC (Fusion) for the issuance and purchase of Neoprobe common stock. Under the stock purchase agreement, Fusion committed to purchase up to \$10 million of Neoprobe common stock over a forty-month period that commences in May 2002. A registration statement registering for resale of up to 5 million shares of Neoprobe common stock was declared effective on April 15, 2002. The Company will be able to request daily draw downs, subject to a daily base amount, currently set at \$12,500. The number of shares the Company is to issue to Fusion in return for that money will be based on the lower of (a) the closing sale price for Neoprobe common stock on the day of the draw request or (b) the average of the three lowest closing sales prices during a twelve day period prior to the draw request. No shares may be sold to Fusion at lower than a floor price currently set at \$0.30, but in no case below \$0.20 without Fusion's prior consent. Upon execution of the common stock purchase agreement, the Company issued 449,438 shares of Neoprobe common stock to Fusion as a commitment fee. The Company intends to draw on the equity line to fund development and commercialization activities as market conditions permit and as considered appropriate.

During February 2002, the Company entered into a line of credit facility with an investment management company. The facility provides for a maximum line of credit of \$2.0 million and is fully collateralized by pledged cash and investments on deposit with the investment management company. Availability under the facility is based on advance rates varying from 80% to 92% of the underlying available collateral. Outstanding amounts under the facility bear interest at LIBOR plus 175 basis points. The facility expires in February 2007. There was no outstanding balance under the line of credit as of March 31, 2002.

The Company believes its current cash position, cash expected to be provided through sales of its gamma detection products, cash available from Fusion and the line of credit are adequate to sustain the Company's planned blood flow and gamma detection development and operations through the fourth quarter of 2002. However, the Company's ability to execute its plans into 2003 significantly depends on its ability to raise additional funds from sources other than operations. The Company's future liquidity and capital requirements will depend on a number of factors, including its ability to raise additional capital in a timely manner through additional investment, expanded market acceptance of its current products, its ability to commercialize new products such as its blood flow product line, its ability to monetize its investment in non-core technologies, its ability to obtain milestone or development funds from potential development and distribution partners, regulatory actions by the FDA and other international regulatory bodies, and intellectual property protection.

There can be no assurance that the additional capital the Company may require to finance operations beyond 2002 will be available on acceptable terms, if at all. Any failure to secure additional financing will force the Company to modify its business plan. There can be no assurance that the Company will be able to achieve significant product revenues from its current or potential new products. In addition, there can be no assurance that the Company will achieve profitability again in the future.

FORWARD-LOOKING STATEMENTS

Our company and its representatives may from time to

time make written or verbal forward-looking statements, including statements contained in this report and other Company filings with the Securities and Exchange Commission and in our reports to shareholders. Statements that relate to other than strictly historical facts, such as statements about our plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for our products are forward-looking statements. Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "will" and other similar expressions identify forward-looking statements. The forward-looking statements are and will be based on our management's then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, our company's limited revenues, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and exclusive distributor, uncertainty of market acceptance, competition, limited marketing and manufacturing experience, and other risks detailed in our company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. We undertake no obligation to publicly update or revise any forward-looking statements.

PART II - OTHER INFORMATION

ITEM 6. Exhibits and Reports on Form 8-K

(a) LIST OF EXHIBITS

None.

(b) REPORTS ON FORM 8-K

The registrant filed a current report on Form 8-K on January 8, 2002, reporting its acquisition of Cardiosonix Ltd. (formerly Biosonix Ltd.) on December 31, 2001.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NEOPROBE CORPORATION
(the Company)
Dated: May 15, 2002

By: /s/ DAVID C. BUPP

David C. Bupp
President and Chief Executive Officer
(duly authorized officer; principal executive officer)

By: /s/ BRENT L. LARSON

Brent L. Larson
Vice President, Finance and Chief Financial Officer
(principal financial and accounting officer)